

TRACK RECORD OF THE PUBLIC ISSUES MANAGED BY THE MERCHANT BANKER IN THE LAST 3 FINANCIAL YEARS

Name of the Issue: Suraksha Diagnostic Limited

- 
1. Type of Issue (IPO/FPO) IPO
2. Issue Size (Rs. Cr) INR 846.25 Cr
3. Grade of issue along with name of the rating agency
- Name NA
- Grade NA
4. Subscription Level (Number of times) 1.2635 times (excluding Anchor Portion) as per the bid book of BSE and NSE (excluding the multiple, duplicate bids, Cancelled bids or withdrawal bids, RC 10 and Other than RC 10.)

Source: Minutes of the Meeting held for the finalization of the Basis of Allotment dated December 4, 2024

5. QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges

Particulars	Percentage
(i) allotment in the issue	32.32 %
(ii) at the end of the 1st Quarter immediately after the listing of the issue <sup>#</sup>	35.83%
(iii) at the end of 1st FY (March 31, 2025) <sup>##</sup>	36.51%
(iv) at the end of 2nd FY (March 31, 2026) <sup>^</sup>	NA
(v) at the end of 3rd FY (March 31, 2027) <sup>^</sup>	NA

(\*) As per the shareholding pattern as on the date of listing.

<sup>#</sup> Source : Shareholding Pattern as on December 31, 2024

<sup>##</sup> Source : Shareholding Pattern as on March 31, 2025

<sup>(^)</sup> QIB Holding not disclosed as reporting for relevant period / fiscal years has not been completed.

6. Financials of the issuer (as per the annual financial results submitted to stock exchanges)

Consolidated

(Rs in Crores)

Parameters	1st FY (March 31, 2025) <sup>#</sup>	2nd FY (March 31, 2026) <sup>*</sup>	3rd FY (March 31, 2027) <sup>*</sup>
Income from operations	252.09	N.A.	N.A.
Net Profit for the period	30.98	N.A.	N.A.
Paid-up equity share capital	10.42	N.A.	N.A.
Reserves excluding revaluation reserves	200.82	N.A.	N.A.

\* Financials not disclosed as reporting for the relevant fiscal years has not been completed.

<sup>#</sup> Source : Audited Financial Results of FY 24-25

## 7. Trading Status in the scrip of the issuer

Company's Equity Shares are listed on the BSE Limited and the National Stock Exchange of India Limited .

Particulars	Status
(i) at the end of 1st FY (March 31, 2025)	Frequently Traded
(ii) at the end of 2nd FY (March 31, 2026)*	N.A.
(iii) at the end of 3rd FY (March 31, 2027)*	N.A.

\* Trading status not disclosed as reporting for the relevant fiscal years has not been completed

## 8. Change in Directors of issuer from the disclosures in the offer document

Particulars	Name of the Director	Appointed/ Resigned
(i) at the end of 1st FY (March 31, 2025)	Nil	Nil
(ii) at the end of 2nd FY (March 31, 2026)*	N.A.	N.A.
(iii) at the end of 3rd FY (March 31, 2027)*	N.A.	N.A.

\*Changes in directors not disclosed as reporting for relevant fiscal years has not been completed

Following Changes in directors have been updated till November 15, 2025.

- 1) Resignation of Mr. Arun Sadhanandham (DIN: 08445197), Non-Executive Non- Independent (Nominee) Director (nominated by OrbiMed Asia II Mauritius Limited) with effect from close of business hours on Friday, 06 June 2025

## 9. Status of implementation of project/ commencement of commercial production

- As disclosed in the offer document:** Not Applicable
- Actual implementation:** Not Applicable
- Reasons for delay in implementation, if any:** Not Applicable

## 10. Status of utilization of issue proceeds

- As disclosed in the offer document:**  
The objects of the Offer are to (i) carry out the Offer for Sale of up to 19,189,330 Equity Shares of face value ₹ 2 each aggregating to ₹ 8,462.49 million by the Selling Shareholders; and (ii) achieve the benefits of listing the Equity Shares on the Stock Exchanges
- Actual utilization:** Not Applicable
- Reasons for deviation, if any:** Not Applicable.

## 11. Comments of monitoring agency, if applicable

(a) Comments on use of funds	Not Applicable, as the Offer is an offer for sale of Equity Shares, the Company is not required to appoint a monitoring agency for the Offer.
(b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document	
(c) Any other reservations expressed by the monitoring agency about the end use of funds	

## 12. Pricing Data

**Issue Price (Rs.): 441 /-**

**Designated Stock Exchange:** BSE Limited

**Listing Date:** December 6, 2024

Price parameters	At close of listing day (i.e. December 6, 2024)	At close of 30th calendar day from listing day#	At close of 90th calendar day from listing day	As at the end of 1st FY after the listing of the issue (March 31, 2025)		
				Closing price	High (during the FY)	Low (during the FY)
Market Price on Designated Stock Exchange (BSE)	417.95	377.85	277.35	257.80	449.00	233.15
BSE Sensex	81,709.12	79,223.11	73730.23	77,414.92	85,978.25	70,234.43
Sectoral Index	NA	NA	NA	NA	NA	NA

Price parameters	As at the end of 2nd FY after the listing of the issue (March 31, 2026)*			As at the end of 3rd FY after the listing of the issue (March 31, 2027)*		
	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
Market Price on Designated Stock Exchange (BSE)	NA	NA	NA	NA	NA	NA
BSE Sensex	NA	NA	NA	NA	NA	NA
Sectoral Index	NA	NA	NA	NA	NA	NA

Source: BSE website

\* Pricing Data not disclosed as reporting for the relevant fiscal years has not been completed

# 30<sup>th</sup> day being non-working day i.e. Saturday 4<sup>th</sup> January, 2025, hence data has been taken of previous working day i.e. 3<sup>rd</sup> January, 2025

**13. Basis for Issue Price (Source of accounting ratios of peer group and industry average may be indicated; Source of the accounting ratios may generally be the same, however in case of different sources, reasons for the same may be indicated)**

Accounting Ratio		As disclosed in the offer document <sup>(1)</sup>	At the end of 1st FY (March 31, 2025) <sup>(3)</sup>	At the end of 2nd FY (March 31, 2026) <sup>(2)</sup>	At the end of 3rd FY (March 31, 2027) <sup>(2)</sup>
EPS	<b>Issuer:</b>	--	--	--	--
	Consolidated (Basic)	4.43	5.97	N.A	N.A
	Consolidated (Diluted)	4.43	5.97	N.A	N.A
	Peer Group :	--	--	--	--
	Dr Lal Path Labs	Basic – 43.05 Diluted – 42.98	Basic – 58.48 Diluted – 58.40	N.A	N.A
	Metropolis Healthcare	Basic – 24.95 Diluted – 24.87	Basic – 28.29 Diluted – 28.15	N.A	N.A
	Thyrocare	Basic – 13.42 Diluted – 13.40	Basic – 17.13 Diluted – 17.08	N.A	N.A
	Vijaya Diagnostic	Basic – 11.62 Diluted – 11.59	Basic – 13.95 Diluted – 13.92	N.A	N.A
	Industry Avg:	N.A	N.A	N.A	N.A
P/E	<b>Issuer:</b>	--	--	--	--
	Consolidated	99.55	43.18	N.A	N.A
	Peer Group	--	--	--	--
	Dr Lal Path Labs	77.08	42.38	N.A	N.A

	Metropolis Healthcare	89.61	55.24	N.A	N.A
	Thyrocare	65.52	39.71	N.A	N.A
	Vijaya Diagnostic	86.40	72.17	N.A	N.A
	Industry Composite:	79.65	N.A	N.A	N.A
RoNW (%)	<b>Issuer:</b>	--	--	--	--
	Consolidated	14.09	14.67	N.A	N.A
	Peer Group	--	--	--	--
	Dr Lal Path Labs	20.35	22.65	N.A	N.A
	Metropolis Healthcare	12.26	10.93	N.A	N.A
	Thyrocare	13.34	16.60	N.A	N.A
	Vijaya Diagnostic	19.77	18.07	N.A	N.A
	Industry Composite:	NA	N.A	N.A	N.A
NAV	<b>Issuer:</b>	--	--	--	--
	Consolidated	33.66	40.55	N.A	N.A
	Peer Group	--	--	--	--
	Dr Lal Path Labs	221.53	259.89	N.A	N.A

	Metropolis Healthcare	213.98	256.94	N.A	N.A
	Thyrocare	99.48	103.18	N.A	N.A
	Vijaya Diagnostic	64.21	77.55	N.A	N.A
	Industry Avg:	N.A	N.A	N.A	N.A

**Notes:**

- (1) Prospectus dated December 3, 2024.  
(2) Not disclosed as the reporting for the relevant fiscal years has not been completed.  
(3) Source : Audited Financial for the FY 24-25

**14. Any other material information**

Particulars	Date
The Company has informed about the resignation of Mr. Bhaskar Ghoshal, Chief Operating Officer of the Company with effect from 12 <sup>th</sup> December, 2024,	12-December-2024
The Company has informed about the formation of Special Purpose Vehicle Company (SPV) between Suraksha Diagnostic Limited and Suraksha Diagnostic & Eye Centre Private Limited, along with the subscription to the equity shares of the SPV.  The Company further informed that the SPV will primarily focusing on the establishment, operation, maintenance and management of 1.5 Tesla MRI Centre at Kolkata Medical College and Hospital, Kolkata on Public Private Partnerships (PPP) mode.	20-December- 2024
The Company has informed about the change of its Corporate Identification Number pursuant to the listing of Equity Shares of the Company on BSE Limited ("BSE") and on the National Stock Exchange of India Limited ("NSE")	08-January-2025
The Company has informed about the resignation of Mr. Amit Saraf, Chief Financial Officer of the Company with effect from 15 <sup>th</sup> February, 2025,	16- January -2025
The Company has informed that pursuant to its intimation about the formation of Special Purpose Vehicle Company (SPV), the company has incorporated on 18 <sup>th</sup> January, 2025 subsidiary company in the name of "Suraksha Advanced Radiology Private Limited" Having its registered office at Plot No. DG-12/1, Action Area 1D, Premises No 02-0327, New Town, North 24 Parganas, Kolkata- 700 156, West Bengal, India.	22- January -2025
The Company has informed about the appointment of Mr. Ravindra K S, Chief Financial Officer of the Company with effect from 1st March, 2025,	08- February - 2025
The Company has informed about its board's approval for a proposal to make a strategic investment of an amount not exceeding ₹ 5.19 crore in Fetomat Wellness Private Limited ('Fetomat'), in cash, in one or more tranches.  The Company further informed that the abovementioned investment shall be made by way of subscription of equity shares and purchase of equity shares from its existing shareholders, subject to compliance with the applicable laws, statutory approvals, consents and permissions, as may be required.	27-March-2025
The Company has informed about the signing of all the definitive agreements and all other transaction related documents with respect to the strategic investment by Suraksha Diagnostic Limited ('the Company') for an amount not exceeding ₹ 5.19 crore in Fetomat Wellness Private Limited ('Fetomat'), in cash, in one or more tranches ('Acquisition').	07-April-2025

The Company has informed about the completion of its acquisition of 63% stake in the Fetomat Wellness Private Limited.	09-April-2025
The Company has informed about the appointment of M/s Pramod Agarwal & Co. (Firm Registration No.: S2002WB057700; Peer Review: 977/2020), Practicing Company Secretaries, as Secretarial Auditor to conduct the secretarial audit of the Company for a term of five (5) consecutive financial years i.e. from FY 2025-26 up to FY 2029-30, subject to the approval of shareholders of the Company at the ensuing Annual General Meeting	28-May-2025
The Company has informed about the launch of one of the largest and a state-of-the-art genomics labs in Eastern India with a grand inauguration event which was graced by Prof. Sukumar Mukherjee, a distinguished rheumatologist with more than 35 years of extensive experience in the field and a mentor at Suraksha Diagnostic	04-July-2025
The Company has informed that Crisil Ratings Limited ('Crisil'), has migrated the rating on the long-term bank facilities of the Company from 'Crisil B (Issuer Not Cooperating) / Stable' to 'Crisil A- / Stable' and has assigned its 'Crisil A2+' rating on the short-term bank facilities of the Company on 08 October 2025.	09-October-2025

Source- Stock Exchange Filings

All the above information has been updated till November 15, 2025, unless indicated otherwise.